23/10/2025
It's time for Top Five's from Episode 168! First up, Luke! 👨⚕️ For new listeners, our Top Five segment consists of each doc's clinical pearls from the articles discussed in that episode 🤓
➡Cidofovir is a deoxycytidine monophosphate analogue that inhibits viral DNA synthesis and binds 35-40 x more avidly to viral vs. human DNA polymerases.
➡Intralesional cidofovir can be given for recalcitrant warts; IV formulation is commonly diluted for IL use (often ~15 mg/mL) and injected into lesions using serial puncture or cross-hatching techniques.
➡IL or topical cidofovir demonstrates ~50% response in case reports for common, plantar, periungual, flat, and ge***al warts. Response is often seen between 1-3 months.
➡Cidofovir can be used for acyclovir-resistant HSV because it does not require viral thymidine kinase activation unlike acyclovir/valacyclovir.
➡Cidofovir may have antineoplastic and antiproliferative effects, making it a potential option for HPV-induced SCCs, BCCs, HSIL, CIN, erythroplasia of Queyrat, lentigo maligna, and EBV-related nasopharyngeal carcinoma.